Navigation Links
Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update
Date:11/7/2011

MOUNTAIN VIEW, Calif., Nov. 7, 2011 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the fiscal quarter ended September 30, 2011 and provided a business update.  The net losses for the quarters ended September 30, 2011 and 2010, as reported in accordance with accounting principles generally accepted in the United States (GAAP), were $13.4 million and $0.6 million, respectively.  The net losses for the nine-month periods ended September 30, 2011 and 2010, were $30.8 million and $26.9 million, respectively.  At September 30, 2011, Alexza had consolidated cash, cash equivalents and marketable securities of $28.3 million.

"Since the acceptance of the resubmission of our ADSUVE NDA in August, we have made additional progress toward our corporate goals for 2011." said Thomas B. King, President and CEO of Alexza.  "We confirmed the FDA advisory committee meeting date on December 12, 2011 to discuss the ADASUVE NDA and we continue to look toward our PDUFA goal date of February 4, 2012."

King continued, "At the same time, we have also made great strides internationally. In addition to submitting the Marketing Authorization Application to the EMA, we announced a partnership with Grupo Ferrer to commercialize ADASUVE in Europe, Latin America, Russia, and the Commonwealth of Independent States (CIS) countries.  We believe we are poised to enter 2012 with momentum as we continue developing ADASUVE."

Alexza Business Update

The following key events, listed in chronological order, occurred since the beginning of the third quarter of 2011:

  • Alexza conducted a face-to-face meeting with the European Medicines Agency (EMA) assigned Co-Rapporteur and his review team in July 2011.
  • In August 2011, the U.S. Food and Drug Administration (FDA) accepted Alexza's resubmission of the Adasuve͐
    '/>"/>

  • SOURCE Alexza Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Alexza Pharmaceuticals to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
    2. Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
    3. Alexza Announces the Adasuve™ (Staccato® Loxapine) PDAC Meeting Date of December 12, 2011
    4. Alexza Pharmaceuticals to Present at the 18th Annual NewsMakers in the Biotech Industry Conference
    5. Alexza and Grupo Ferrer Establish Partnership for the Commercialization of Adasuve™ (Staccato® Loxapine) in Europe and Latin America
    6. Alexza Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
    7. Alexza Announces Adasuve™ (Staccato® Loxapine) PDUFA Goal Date of February 4, 2012
    8. Alexza Announces Resubmission of AZ-004 (Staccato® Loxapine) NDA
    9. Alexza to Announce 2011 Second Quarter Financial Results on Monday, August 8, 2011
    10. Alexza Reports 2011 First Quarter Financial Results and Provides Business Update
    11. Alexza to Present at the MDB Bright Lights Conference 2011
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- Market ... Hydrochloride Industry, 2009-2019 is a professional and ... Oxybutynin Hydrochloride industry. The report firstly reviews ... its classification, application and manufacturing technology. The ... manufacturers of Oxybutynin Hydrochloride listing their product ...
    (Date:9/19/2014)... CHICAGO, Ill. , Sept. 19, 2014  The ... ABBV ) declared a quarterly cash dividend of $0.42 ... payable Nov. 17, 2014 to stockholders of record at ... About AbbVie AbbVie is a global, research-based biopharmaceutical ... company,s mission is to use its expertise, dedicated people ...
    (Date:9/19/2014)... -- Merck (NYSE: MRK ), known as MSD outside ... , is teaming with celebrity chef and cookbook author Leticia ... an educational program encouraging Hispanics with type 2 diabetes to achieve ... to help reduce the risk of serious health problems. Hispanics in ... risk for developing type 2 diabetes than non-Hispanic white adults, and ...
    Breaking Medicine Technology:Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5
    (Date:9/22/2014)... 2014 One key emerging trend in ... investing in R&D to develop new and advanced biomaterial ... implants. The introduction of third-generation orthopedic biomaterials such as ... will increase the growth of the market in the ... market to grow at a CAGR of 10.78 ...
    (Date:9/22/2014)... (PRWEB) September 22, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Twix . , ... Twix Unwrapped Bites 7 oz. Stand Up Pouch with specific ... for the recall is that Twix Unwrapped Bites ... contain peanuts and eggs without writing them on the ingredient ...
    (Date:9/22/2014)... In CHAMPS Patient Experience's most recent blog ... Summer Meeting , Toya Gorley shares her thoughts on ... The Leader’s Board meeting this summer, which was comprised ... experience to be exhilarating! Many topics were discussed, including:, ... on the patient experience , Technology ...
    (Date:9/22/2014)... September 22, 2014 Fancyflyingfox.com, the well-known wedding ... of 2014 plus size wedding dresses . In addition, ... for these fashionable plus size outfits. Each item in the ... up to 65% off. , The company has thousands ... them are now available at extremely affordable prices. Its products ...
    (Date:9/21/2014)... cancer patients who smoke, those using e-cigarettes (in addition ... or less likely to have quit smoking traditional cigarettes ... a peer-reviewed journal of the American Cancer Society, the ... for helping cancer patients give up smoking. , Because ... who smoke should be advised to quit. But the ...
    Breaking Medicine News(10 mins):Health News:Orthopedic Biomaterials Market to Grow at 10.78% CAGR by 2018, Forecasts a New Research Report at ReportsnReports.com 2Health News:Orthopedic Biomaterials Market to Grow at 10.78% CAGR by 2018, Forecasts a New Research Report at ReportsnReports.com 3Health News:Orthopedic Biomaterials Market to Grow at 10.78% CAGR by 2018, Forecasts a New Research Report at ReportsnReports.com 4Health News:Mars Chocolate North America Recalls Twix Bites: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:CHAMPS' Toya Gorley Discusses the Thought-Provoking Conversation at The Leader’s Board Summer Meeting 2Health News:Discounted Plus Size Wedding Dresses Available At Fancyflyingfox.com 2Health News:E-cigarettes unhelpful in smoking cessation among cancer patients 2
    ... a changed version of dopamine// transporter in healthy ... with substance abuse or attention deficit hyperactivity disorder ... the hypothalamus and some areas of the central ... play an important role in hormonal, cardiovascular, renal ...
    ... is possible to increase the heights of children who ... improved dosages of the growth hormones. ,The researchers ... that the administration of the growth hormone GH-dependent hormone ... (IGF-I) can affect the growth of children in height. ...
    ... have found out new information about how neuro ... be possibly slowed. ,Researchers at the Rocky ... found novel insights into how abnormal prion proteins ... mice producing prion protein without a glycophosphoinositol (GPI) ...
    ... be used to detect cancer, says a new study that ... and son research team had been able to bind the ... that will make the tracing of cancer cells much easier. ... factor receptor (EFGR) over their surface. This protein is not ...
    ... be at less risk from colorectal// cancer. And women who ... B may have even reduced chance of having colorectal cancer. ... of abnormal or malignant cells within the lining of colon ... American researchers, said that inadequate intake of dietary vitamin B ...
    ... problems// like cognitive impairment in children. ,Researchers across the ... of pollutants like noise from the traffic and aircrafts on ... of 2844 children in the age group of 9 to ... Netherlands, Spain, and UK. Researchers had taken the help of ...
    Cached Medicine News:
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: